Davis Polk advised the representatives of the several underwriters in connection with the $100.5 million initial public offering of 6,700,000 common shares of LAVA Therapeutics N.V. The common shares are listed on the Nasdaq Global Select Market under the symbol “LVTX.”
Headquartered in Utrecht, the Netherlands, LAVA Therapeutics is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Joze Vranicar. Partner David R. Bauer and associate Hilary Smith provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.